The activation of GPR119 promotes glucose-stimulated insulin secretion and GLP-1 release, thus GPR119 is considered to be a potential therapeutic target for the treatment of type 2 diabetes [2, 11, 12]. This evidence concerns the gene GCG and type 2 diabetes mellitus.